FindTrial
Sign In

GSK2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanoma

GSK2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanoma

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221174
Enrollment
Unknown
Registered
2010-08-02
Start date
2010-08-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melanoma

Interventions

investigational material(s) Generic name etc : GSK2132231A INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational mater

Sponsors

GlaxoSmithKline K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Refer to 'GSK Clinical Study Register'

Exclusion criteria

Exclusion criteria: Refer to 'GSK Clinical Study Register'

Design outcomes

Primary

MeasureTime frame
Refer to 'GSK Clinical Study Register' Refer to 'GSK Clinical Study Register'—

Secondary

MeasureTime frame
Refer to 'GSK Clinical Study Register' Refer to 'GSK Clinical Study Register'—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026